argenx utilizes role-specific work policies rather than a company-wide remote-first structure. Field-based clinical affairs, medical science liaison, and commercial positions allow employees to work remotely from home offices while requiring regular regional travel for clinical site visits and stakeholder engagements. Administrative, laboratory research, and executive leadership roles are primarily based out of corporate office locations or follow hybrid schedules.

argenx develops and commercializes targeted antibody therapies for patients with severe autoimmune diseases. Its flagship commercial product, VYVGART (efgartigimod), targets the neonatal Fc receptor to clear disease-causing IgG antibodies. The company also advances clinical pipeline research across neuromuscular, hematologic, and dermatologic indications while offering specialized patient education and support services.

Headquartered in Amsterdam, Netherlands, argenx operates across Europe, North America, and Asia-Pacific. The company maintains its primary U.S. operational headquarters in Boston, Massachusetts, along with regional corporate and clinical trial offices in Belgium, Germany, Switzerland, the United Kingdom, Canada, Japan, and Australia. Its approved biopharmaceutical therapies are available to patients across more than 30 countries globally.